moatshark My

All holdings

Regeneron Pharmaceuticals

REGN

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
3
In their latest 13F (Q3 2026)
See who
Value held
$3.1bn
Combined value at quarter end
Last quarter
2 bought
1 sold or trimmed
Fund portfolios
2
Funds holding it
See which
Price at Q2 ’26 end
$623.54
-19.3% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

0.0%Q3 ’24
-32.2%Q4 ’24
-11.0%Q1 ’25
-17.2%Q2 ’25
+7.1%Q3 ’25
+37.3%Q4 ’25
+0.1%Q1 ’26
-19.3%Q2 ’26
Q3 ’24: 0.0%; Q4 ’24: -32.2%; Q1 ’25: -11.0%; Q2 ’25: -17.2%; Q3 ’25: +7.1%; Q4 ’25: +37.3%; Q1 ’26: +0.1%; Q2 ’26: -19.3%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

2Q4 ’23
2Q1 ’24
2Q2 ’24
2Q3 ’24
2Q4 ’24
3Q1 ’25
3Q2 ’25
3Q3 ’25
3Q4 ’25
3Q1 ’26
3Q2 ’26
0Q3 ’26
Q4 ’23: 2; Q1 ’24: 2; Q2 ’24: 2; Q3 ’24: 2; Q4 ’24: 2; Q1 ’25: 3; Q2 ’25: 3; Q3 ’25: 3; Q4 ’25: 3; Q1 ’26: 3; Q2 ’26: 3; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Regeneron Pharmaceuticals.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Regeneron Pharmaceuticals
Southeastern Asset Management5.0%$95.0m$95.0mAdded +17%6 qtrs
Dodge & Cox1.6%$3.0bn$3.0bnAdded +9.3%19 qtrs
Horizon Kinetics0.0%$402k$402kTrimmed -4.4%14 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Regeneron Pharmaceuticals
Bought or soldFiling
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold463$780.63$361kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold454$778.64$354kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold380$779.59$296kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold376$775.46$292kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold283$771.56$218kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold279$766.47$214kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold271$765.39$207kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold224$773.40$173kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold219$764.40$167kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold211$772.56$163kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold192$767.39$147kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold127$769.30$98kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold121$774.48$94kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold105$768.33$81kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold74$760.65$56kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold66$776.31$51kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold55$762.57$42kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold50$781.47$39kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold38$777.76$30kForm 4
14 Oct 2026Murphy Andrew JCo-Chief Scientific Officer▼ Sold35$755.91$26kForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
New York
Financial year ends
31 December
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$2.1bn2013
$4.1bn2015
$5.9bn2017
$6.6bn2019
$16bn2021
$13bn2023
$14bn2025
2013: $2.1bn; 2014: $2.8bn; 2015: $4.1bn; 2016: $4.9bn; 2017: $5.9bn; 2018: $5.1bn; 2019: $6.6bn; 2020: $8.5bn; 2021: $16bn; 2022: $12bn; 2023: $13bn; 2024: $14bn; 2025: $14bn
Regeneron Pharmaceuticals revenue and net income by year
YearRevenueNet income
2025$14bn$4.5bn
2024$14bn$4.4bn
2023$13bn$4.0bn
2022$12bn$4.3bn
2021$16bn$8.1bn
2020$8.5bn$3.5bn
2019$6.6bn$2.1bn
2018$5.1bn$2.4bn
2017$5.9bn$1.2bn
2016$4.9bn$896m
2015$4.1bn$636m
2014$2.8bn$338m
2013$2.1bn$414m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Regeneron Pharmaceuticals, from their latest N-PORT filings.

Funds holding Regeneron Pharmaceuticals
Longleaf Partners Global FundSoutheastern Asset Management4.8%$33.0m30 Jun 2026
Dodge & Cox Global Stock FundDodge & Cox1.4%$187m30 Jun 2026